Opposing roles for CD34 in B16 melanoma tumor growth alter early stage vasculature and late stage immune cell infiltration

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Maltby, Steven ^a   Freeman, Spencer ^a   Gold, Matthew J ^a   Baker, Jennifer H E ^a   Minchinton, Andrew I ^a   Gold, Michael R ^a   Roskelley, Calvin D ^a   McNagny, Kelly M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CARBOCYANINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN FUNCTION; ARTICLE; BLOOD VESSEL PERMEABILITY; BONE MARROW TRANSPLANTATION; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; DISEASE MODEL; GROWTH RATE; HEMATOPOIESIS; IMMUNOCOMPETENT CELL; LUNG METASTASIS; MAST CELL; MELANOMA; METASTASIS POTENTIAL; MOUSE; NONHUMAN; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; WILD TYPE; ANIMAL; BIOLOGICAL MODEL; CANCER STAGING; CAPILLARY PERMEABILITY; CELL PROLIFERATION; EXPERIMENTAL MELANOMA; HEMATOPOIETIC SYSTEM; METABOLISM; METASTASIS; PATHOLOGY; PATHOPHYSIOLOGY; SUBCUTANEOUS TISSUE; TIME; TUMOR ASSOCIATED LEUKOCYTE; VASCULARIZATION;

MUS;

ANIMALS; ANTIGENS, CD34; CAPILLARY PERMEABILITY; CARBOCYANINES; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HEMATOPOIETIC SYSTEM; LYMPHOCYTES, TUMOR-INFILTRATING; MAST CELLS; MELANOMA, EXPERIMENTAL; MICE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASM STAGING; SUBCUTANEOUS TISSUE; TIME FACTORS; TUMOR MICROENVIRONMENT;

EID: 79954547294     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018160     Document Type: Article

References (31)

1. Hanahan D, Folkman J, (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364.
2. Folkman J, Watson K, Ingber D, Hanahan D, (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61.
3. Ribatti D, Crivellato E, Roccaro AM, Ria R, Vacca A, (2004) Mast cell contribution to angiogenesis related to tumour progression. Clin Exp Allergy 34: 1660-1664.
4. Delia D, Lampugnani MG, Resnati M, Dejana E, Aiello A, et al. (1993) CD34 expression is regulated reciprocally with adhesion molecules in vascular endothelial cells in vitro. Blood 81: 1001-1008.
5. Radinger M, Johansson AK, Sitkauskiene B, Sjostrand M, Lotvall J, (2004) Eotaxin-2 regulates newly produced and CD34 airway eosinophils after allergen exposure. J Allergy Clin Immunol 113: 1109-1116.
6. Blanchet MR, Maltby S, Haddon DJ, Merkens H, Zbytnuik L, et al. (2007) CD34 facilitates the development of allergic asthma. Blood 110: 2005-2012.
7. Maltby S, Wohlfarth C, Gold M, Zbytnuik L, Hughes MR, et al. (2010) CD34 is required for infiltration of eosinophils into the colon and pathology associated with DSS-induced ulcerative colitis. Am J Pathol 177: 1244-1254.
8. Drew E, Huettner CS, Tenen DG, McNagny KM, (2005) CD34 expression by mast cells: Of mice and men. Blood 106: 1885-1887.
9. Baumheter S, Singer MS, Henzel W, Hemmerich S, Renz M, et al. (1993) Binding of L-selectin to the vascular sialomucin CD34. Science 262: 436-438.
10. Strilic B, Kucera T, Eglinger J, Hughes MR, McNagny KM, et al. (2009) The molecular basis of vascular lumen formation in the developing mouse aorta. Dev Cell 17: 505-515.
11. Blanchet MR, Gold M, Maltby S, Bennett J, Petri B, et al. (2010) Loss of CD34 leads to exacerbated autoimmune arthritis through increased vascular permeability. J Immunol 184: 1292-1299.
12. Drew E, Merzaban JS, Seo W, Ziltener HJ, McNagny KM, (2005) CD34 and CD43 inhibit mast cell adhesion and are required for optimal mast cell reconstitution. Immunity 22: 43-57.
13. Murdoch C, Muthana M, Coffelt SB, Lewis CE, (2008) The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8: 618-631.
14. Maltby S, Khazaie K, McNagny KM, (2009) Mast cells in tumor growth: Angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 1796: 19-26.
15. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, et al. (1999) Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 13: 1382-1397.
16. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, et al. (2007) Mast cells are required for angiogenesis and macroscopic expansion of myc-induced pancreatic islet tumors. Nat Med 13: 1211-1218.
17. Gounaris E, Erdman SE, Restaino C, Gurish MF, Friend DS, et al. (2007) Mast cells are an essential hematopoietic component for polyp development. Proc Natl Acad Sci U S A 104: 19977-19982.
18. Mattes J, Hulett M, Xie W, Hogan S, Rothenberg ME, et al. (2003) Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: An eotaxin and STAT6-dependent process. J Exp Med 197: 387-393.
19. Cormier SA, Taranova AG, Bedient C, Nguyen T, Protheroe C, et al. (2006) Pivotal advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol 79: 1131-1139.
20. Murakami J, Li TS, Ueda K, Tanaka T, Hamano K, (2009) Inhibition of accelerated tumor growth by blocking the recruitment of mobilized endothelial progenitor cells after chemotherapy. Int J Cancer 124: 1685-1692.
21. Chen L, Lu Y, Wu JM, Xu B, Zhang LJ, et al. (2009) Ligustrazine inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by vascular endothelial growth factor. Biochem Biophys Res Commun 386: 374-379.
22. Tardio JC, (2008) CD34-reactive tumors of the skin. an updated review of an ever-growing list of lesions. J Cutan Pathol 35: 1079-1092.
23. Trempus CS, Morris RJ, Ehinger M, Elmore A, Bortner CD, et al. (2007) CD34 expression by hair follicle stem cells is required for skin tumor development in mice. Cancer Res 67: 4173-4181.
24. Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, et al. (2010) Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 177: 1031-1041.
25. Quon H, Hasbini A, Cougnard J, Djafari L, Lacroix C, et al. (2010) Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma. J Neurooncol 96: 277-285.
26. Starkey JR, Crowle PK, Taubenberger S, (1988) Mast-cell-deficient W/Wv mice exhibit a decreased rate of tumor angiogenesis. Int J Cancer 42: 48-52.
27. Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, et al. (2007) Regulation of carcinogenesis by IL-5 and CCL11: A potential role for eosinophils in tumor immune surveillance. J Immunol 178: 4222-4229.
28. Suzuki A, Andrew DP, Gonzalo JA, Fukumoto M, Spellberg J, et al. (1996) CD34-deficient mice have reduced eosinophil accumulation after allergen exposure and show a novel crossreactive 90-kD protein. Blood 87: 3550-3562.
29. Kyle AH, Huxham LA, Yeoman DM, Minchinton AI, (2007) Limited tissue penetration of taxanes: A mechanism for resistance in solid tumors. Clin Cancer Res 13: 2804-2810.
30. Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, et al. (2008) Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 14: 2171-2179.
31. Freeman SA, McLeod SJ, Dukowski J, Austin P, Lee CC, et al. (2010) Preventing the activation or cycling of the Rap1 GTPase alters adhesion and cytoskeletal dynamics and blocks metastatic melanoma cell extravasation into the lungs. Cancer Res 70: 4590-4601.